Literature DB >> 31484533

Transferrin receptor-1 and VEGF are prognostic factors for osteosarcoma.

Hongzeng Wu1, Jinming Zhang1, Ruoheng Dai2, Jianfa Xu1, Helin Feng3.   

Abstract

BACKGROUND: Osteosarcoma is aggressive and prognostic biomarkers are important to predict the outcomes of surgery and chemotherapy. Here, we investigated the potential of transferrin receptor-1 (TfR1) and vascular endothelial growth factor (VEGF) as prognostic markers of osteosarcoma.
METHODS: TfR1 and VEGF in osteosarcoma samples from a cohort of 53 osteosarcoma patients were detected by immunohistochemistry analysis. The correlation of TfR1 and VEGF levels with clinicopathological parameters was analyzed by Pearson chi-square and Spearman-rho tests. Overall patient survival was analyzed by the Kaplan-Meier method.
RESULTS: We found that TfR1 and VEGF expression levels were low in 20.8% and 18.9%; modest in 35.8% and 35.8%; and high in 43.4% and 45.3% of osteosarcoma patients, respectively. TfR1 and VEGF expression was significantly correlated to histologic grade, Enneking stage, and distant metastasis. TfR1 expression was significantly correlated to VEGF expression and both TfR1 expression and VEGF expression were correlated to shorter overall survival.
CONCLUSIONS: TfR1 and VEGF are potential prognostic factors for osteosarcoma.

Entities:  

Keywords:  Osteosarcoma; Prognosis; Transferrin receptor-1; VEGF

Mesh:

Substances:

Year:  2019        PMID: 31484533      PMCID: PMC6727552          DOI: 10.1186/s13018-019-1301-z

Source DB:  PubMed          Journal:  J Orthop Surg Res        ISSN: 1749-799X            Impact factor:   2.359


Background

Primary bone tumors are uncommon and the incidence is low [1]. Osteosarcoma (OS) is a pleomorphic sarcoma of the bone in children and adult, and OS patients frequently develop metastasis [2]. With the recent development of adjuvant chemotherapy, the 5-year-free survival rate has improved to approximately 50% for patient with high-grade OS [3, 4]. The identification of new prognostic biomarkers in osteosarcoma has become increasingly important to predict the responsiveness of treatment [5]. Iron is an element essential to cellular activities such as DNA synthesis and cell proliferation [6-8]. Proteins involved in iron metabolism have been shown to promote lung cancer [9-11]. Recent studies have shown high expression of transferrin receptor-1 (TfR1) in a variety of tumors including lung, breast, and bladder cancer as well as malignant glioma, but the clinical significance of TfR1 in tumor remains to be confirmed [12, 13]. Angiogenesis plays an important role in tumor development. Vascular endothelial growth factor (VEGF) is known to promote neovascularization [14, 15]. Up to now, the association between TfR1 and VEGF expression and the prognosis of OS patients remains unclear. Therefore, this study aimed to examine TfR1 and VEGF expression in OS patients and analyze their prognostic significance for clinical outcomes of OS.

Methods

Subjects

Ethics Committees of the Fourth Hospital of Hebei Medical University (also named as Tumor Hospital of Hebei Province) approved this study and all patients signed written informed consent. This study enrolled 53 OS patients from 2002 to 2010 from the Fourth Hospital of Hebei Medical University, who had not received radiotherapy or chemotherapy. All patient data and follow-up information were collected, including the gender, age, tumor size, histological grade, Enneking stage, and distant metastasis.

Immunohistochemistry analysis

Immunohistochemistry (IHC) analysis was performed on OS tissues using antibodies for TfR1 (1:100; Biogot Tech) and VEGF (1:100; Santa Cruz Biotechnology), following a previously described protocol [16]. The results of IHC were judged using the following score system based on the percentage of stained cells, < 1% (0); 1–25% (1); 25–50% (2); 51–80% (3); and > 80% (4); and the intensity of staining, no staining (0); weak staining (1); strong staining (2); and very strong staining (3). The final score was the product of staining intensity and percentage and judged as low (0–3 points), mild (4–7 points), and high (> 7 points).

Statistical analysis

All data were analyzed by using SPSS software 25.0. The association of clinical variables was analyzed by the Pearson chi-square test or Spearman-rho test. Univariate and multivariate analyses were performed by using the Cox proportional hazard model. Survival was analyzed by the Kaplan-Meier method. P < 0.05 was considered significant.

Results

Association of TfR1 and VEGF with clinicopathological parameters

Typical staining of TfR1 and VEGF in OS tissues was presented in Fig. 1. TfR1 expression was low in 20.8%, mild in 35.8% and high in 43.4% of OS tissues, whereas VEGF expression was low in 18.9%, mild in 35.8%, and high in 45.3% of OS tissues. As shown in Table 1, TfR1 and VEGF expression was significantly associated with histological grade, Enneking stage and distant metastasis (all P < 0.05). In addition, TfR1 and VEGF expression showed a significantly positive correlation (P < 0.01, Table 2).
Fig. 1

Representative immunohistochemical staining of TfR1 and VEGF. a High expression of TfR1 in OS. c Moderate expression of TfR1 in OS. e Low expression of TfR1 in OS. b High expression of VEGF in OS. d Moderate expression of VEGF in OS. f Low expression of VEGF in OS. The cells with positive expression were stained brown

Table 1

Clinicopathological variables and the expression of TfR1 and VEGF

TfR1 P VEGF P
Low(%)Mild(%)High(%)Low(%)Mild(%)High(%)
SexFemale253(12.0)10(40.0)12(48.0)0.3325(20.0)11(44.0)9(36.0)0.405
Male288(28.6)9(32.1)11(39.3)5(17.8)8(28.6)15(53.6)
Age≥ 20 years184(22.2)4(22.2)10(55.6)0.3063(16.7)9(50.0)6(33.3)0.293
< 20 years357(20.0)15(42.9)13(37.1)7(20.0)10(28.6)18(51.4)
Tumor size< 5 cm276(22.2)10(37.0)11(40.8)0.9196(22.2)10(37.0)11(40.7)0.741
≥ 5 cm265(19.2)9(34.6)12(46.2)4(15.4)9(34.6)13(50.0)
Histologic grade*I154(26.7)8(53.3)3(20.0)0.044(26.7)9(60.0)2(13.3)0.02
II255(20.0)10(40.0)10(40.0)5(20.0)8(32.0)12(48.0)
III132(15.4)1(7.7)10(76.9)1(7.7)2(15.4)10(76.9)
Distant metastasis*Yes231(4.2)11(47.8)11(47.8)0.0291(4.4)13(56.5)9(39.1)0.008
No3010(33.3)8(26.7)12(40.0)9(30.0)6(20.0)15(50.0)
Enneking staging*I128 (66.7)3 (25.0)7(36.9)< 0.0016(50.0)4(33.3)2(16.7)0.004
II192 (10.5)10(52.6)21(43.8%)2(10.5)10(52.6)7(36.9)
III221 (4.5)6 (27.3)15 (68.2)2(9.1)5(22.7)15(68.2)

Pearson’s chi-squared test was used. *P < 0.05

Table 2

The correlation of TfR1 and VEGF expression

CharacteristicsTfR1P (Spearman)
Low(%)Mild(%)High(%)
VEGF*Low106(11.3)3(5.7)1(1.9)= 0.001
Mild192(3.7)10(18.9)7(13.2)
High243(5.7)6(11.3)15(28.3)
53111923

Spearman-rho test was used. *P < 0.05

Representative immunohistochemical staining of TfR1 and VEGF. a High expression of TfR1 in OS. c Moderate expression of TfR1 in OS. e Low expression of TfR1 in OS. b High expression of VEGF in OS. d Moderate expression of VEGF in OS. f Low expression of VEGF in OS. The cells with positive expression were stained brown Clinicopathological variables and the expression of TfR1 and VEGF Pearson’s chi-squared test was used. *P < 0.05 The correlation of TfR1 and VEGF expression Spearman-rho test was used. *P < 0.05

TfR1 and VEGF were correlated with poor overall survival of OS patients

Table 3 showed the results of univariate Cox hazard analysis of overall survival of OS patients. Kaplan-Meier survival curve showed that the gender, age, tumor size, and histologic grade had no significance in predicting overall survival, but Enneking staging and distant metastasis predicted a poor overall survival (Fig. 2). Moreover, TfR1 and VEGF were significantly correlated with poor overall survival (Table 3, Fig. 2).
Table 3

Clinicopathological factors associated with overall survival based on univariate Cox proportional regression analysis

CharacteristicsOverall survival P
HR95% CI
SexFemale2510.837
Male281.0640.590–1.919
Age≥ 20 years1810.777
< 20 years351.0930.591–2.022
Tumor size< 5 cm2710.940
≥ 5 cm261.0240.556–1.884
Histologic grade*I1510.412
II251.2670.634–2.5340.503
III131.7380.771–3.9170.183
Distant metastasis*Yes231< 0.001
No300.1610.073–0.356
Enneking staging*I121< 0.001
II198.6052.942–25.169
III2226.0397.679–88.293
TfR1*Low111< 0.001
Moderate190.1580.063–0.398
High230.3000.143–0.629
VEGF*Low1010.021
Moderate190.1140.043–0.303
High240.4220.202–0.880

HR, hazard ratio; 95% CI, 95% confidence interval. *P < 0.05

Fig. 2

Overall survival curves of patients with OS. a Association of overall survival with distant metastasis. b Association of overall survival with TfR1 expression. c Association of overall survival with VEGF expression. d Association of overall survival with clinical stage

Clinicopathological factors associated with overall survival based on univariate Cox proportional regression analysis HR, hazard ratio; 95% CI, 95% confidence interval. *P < 0.05 Overall survival curves of patients with OS. a Association of overall survival with distant metastasis. b Association of overall survival with TfR1 expression. c Association of overall survival with VEGF expression. d Association of overall survival with clinical stage

TfR1 and VEGF are prognostic factors for OS patients

Table 4 showed the results of multivariate Cox hazard analysis of univariate factors listed in Table 3. Enneking staging, TfR1 expression, and VEGF expression were identified as independent prognostic factors of OS patients. Higher TfR1 and VEGF expression, higher Enneking staging, and distance metastasis were associated with significantly higher mortality risk (Plogrank < 0.001) (Fig. 2).
Table 4

Clinicopathological factors associated with overall survival based on multivariate Cox regression analysis

Overall survival
HR95% CI P
Enneking stage4.6222.541–8.406< 0.001
TfR12.5141.445–4.3720.001
VEGF2.8821.203–8.2170.002

HR, hazard ratio; 95% CI, 95% confidence interval. *P < 0.05

Clinicopathological factors associated with overall survival based on multivariate Cox regression analysis HR, hazard ratio; 95% CI, 95% confidence interval. *P < 0.05

Discussion

As a common malignant bone tumor, OS accounts for 30% of all bone malignancies and 3–4% of pediatric tumors [17]. OS has been reported to be the third most common cancer in adolescence [18]. Therefore, it is important to identify novel biomarkers and therapeutic targets for OS. Abnormal iron metabolism is associated with tumorigenesis [19-21]. Iron homeostasis is maintained by the balance of iron uptake, usage, and storage [22]. TfR1 is the main protein responsible for iron absorption. Strong immunohistochemical staining of TfR1 could indicate high cancer cell proliferation and poor prognosis of cancer patients [23-25]. Tumor cells with high TfR1 expression exhibited a high rate of iron absorption and cell proliferation [26]. To our knowledge, our study was the first to report high expression of TfR1 and VEGF in OS tissues. Moreover, we found that high TfR1 and VEGF expression was significantly correlated to histological grade, Enneking staging, and distant metastasis. Furthermore, high TfR1 and VEGF expression was significantly correlated to poor overall survival, and both TfR1 and VEGF were independent prognostic indicators of OS patients. Our study has several limitations. First, immunohistochemistry analysis is only semi-quantitative, and bias may affect the evaluation of staining score although we analyzed all samples in a blind manner. Second, our sample size is limited. Third, our study is a single-center study.

Conclusions

In summary, TfR1 and VEGF expression is high in OS tissues and is correlated to malignancy grade of OS patients. TfR1 and VEGF are potential prognostic factors of OS patients.
  25 in total

Review 1.  Iron and copper metabolism.

Authors:  Miguel Arredondo; Marco T Núñez
Journal:  Mol Aspects Med       Date:  2005 Aug-Oct

2.  (F-18) fluorodeoxyglucose positron emission tomography as a predictor of pathologic grade and other prognostic variables in bone and soft tissue sarcoma.

Authors:  A L Folpe; R H Lyles; J T Sprouse; E U Conrad; J F Eary
Journal:  Clin Cancer Res       Date:  2000-04       Impact factor: 12.531

3.  Fine needle aspiration of primary mediastinal synovial sarcoma: cytomorphologic, immunohistochemical, and molecular study.

Authors:  Cheng Cheng Huang; Claire W Michael; Judy C Pang
Journal:  Diagn Cytopathol       Date:  2012-08-31       Impact factor: 1.582

Review 4.  Regulation of cellular iron metabolism and its implications in lung cancer progression.

Authors:  Wei Xiong; Li Wang; Fenglei Yu
Journal:  Med Oncol       Date:  2014-05-27       Impact factor: 3.064

Review 5.  Ironing out cancer.

Authors:  Suzy V Torti; Frank M Torti
Journal:  Cancer Res       Date:  2011-03-01       Impact factor: 12.701

Review 6.  The transferrin receptor part I: Biology and targeting with cytotoxic antibodies for the treatment of cancer.

Authors:  Tracy R Daniels; Tracie Delgado; Jose A Rodriguez; Gustavo Helguera; Manuel L Penichet
Journal:  Clin Immunol       Date:  2006-08-10       Impact factor: 3.969

7.  A class of iron chelators with a wide spectrum of potent antitumor activity that overcomes resistance to chemotherapeutics.

Authors:  Megan Whitnall; Jonathan Howard; Prem Ponka; Des R Richardson
Journal:  Proc Natl Acad Sci U S A       Date:  2006-09-26       Impact factor: 11.205

Review 8.  Osteosarcoma treatment - where do we stand? A state of the art review.

Authors:  Anja Luetke; Paul A Meyers; Ian Lewis; Heribert Juergens
Journal:  Cancer Treat Rev       Date:  2013-11-27       Impact factor: 12.111

9.  Transferrin receptor 2 is frequently expressed in human cancer cell lines.

Authors:  Alessia Calzolari; Isabella Oliviero; Silvia Deaglio; Gualtiero Mariani; Mauro Biffoni; Nadia Maria Sposi; Fabio Malavasi; Cesare Peschle; Ugo Testa
Journal:  Blood Cells Mol Dis       Date:  2007-04-10       Impact factor: 3.039

10.  Epidemiology and classification of bone tumors.

Authors:  Alessandro Franchi
Journal:  Clin Cases Miner Bone Metab       Date:  2012-09-30
View more
  13 in total

1.  Detection of Ferritin Expression in Soft Tissue Sarcomas With MRI: Potential Implications for Iron Metabolic Therapy.

Authors:  Michael S Petronek; Ann M Tomanek-Chalkley; Varun Monga; Mohammed M Milhem; Benjamin J Miller; Vincent A Magnotta; Bryan G Allen
Journal:  Iowa Orthop J       Date:  2022-06

2.  Soluble transferrin receptor can predict all-cause mortality regardless of anaemia and iron storage status.

Authors:  Minjung Kang; Soie Kwon; Whanhee Lee; Yaerim Kim; Eunjin Bae; Jeonghwan Lee; Jae Yoon Park; Yong Chul Kim; Eun Young Kim; Dong Ki Kim; Chun Soo Lim; Yon Su Kim; Jung Pyo Lee
Journal:  Sci Rep       Date:  2022-07-13       Impact factor: 4.996

3.  The Efficacy and Safety of Apatinib in Refractory/Relapse Advanced Pediatric Solid Tumor: A Retrospective Study.

Authors:  Feifei Sun; Suying Lu; Zijun Zhen; Jia Zhu; Juan Wang; Junting Huang; Yu Zhang; Hui Li; Ruiqing Cai; Meiling Liu; Liuhong Wu; Xiaofei Sun; Yizhuo Zhang
Journal:  Cancer Manag Res       Date:  2020-07-22       Impact factor: 3.989

Review 4.  Targeting Molecular Mechanisms Underlying Treatment Efficacy and Resistance in Osteosarcoma: A Review of Current and Future Strategies.

Authors:  Ingrid Lilienthal; Nikolas Herold
Journal:  Int J Mol Sci       Date:  2020-09-19       Impact factor: 5.923

5.  The relationship between the expression of Ki-67 and the prognosis of osteosarcoma.

Authors:  Ming Zeng; Jian Zhou; Lifang Wen; Yanshan Zhu; Yingquan Luo; Wanchun Wang
Journal:  BMC Cancer       Date:  2021-03-01       Impact factor: 4.430

Review 6.  Iron Metabolism in the Tumor Microenvironment: Contributions of Innate Immune Cells.

Authors:  Wei Liang; Napoleone Ferrara
Journal:  Front Immunol       Date:  2021-02-12       Impact factor: 7.561

Review 7.  Mechanisms of Resistance to Conventional Therapies for Osteosarcoma.

Authors:  Louise Marchandet; Morgane Lallier; Céline Charrier; Marc Baud'huin; Benjamin Ory; François Lamoureux
Journal:  Cancers (Basel)       Date:  2021-02-08       Impact factor: 6.639

8.  Optimized Doxorubicin Chemotherapy for Diffuse Large B-cell Lymphoma Exploits Nanocarrier Delivery to Transferrin Receptors.

Authors:  Artavazd Arumov; Piumi Y Liyanage; Roger M Leblanc; Jonathan H Schatz; Asaad Trabolsi; Evan R Roberts; Lingxiao Li; Braulio C L B Ferreira; Zhen Gao; Yuguang Ban; Austin D Newsam; Melissa W Taggart; Francisco Vega; Daniel Bilbao
Journal:  Cancer Res       Date:  2020-11-11       Impact factor: 13.312

9.  PENK inhibits osteosarcoma cell migration by activating the PI3K/Akt signaling pathway.

Authors:  Hai-Ping Zhang; Zi-Liang Yu; Bing-Bing Wu; Fa-Rui Sun
Journal:  J Orthop Surg Res       Date:  2020-04-25       Impact factor: 2.359

10.  Development of a novel immune-related genes prognostic signature for osteosarcoma.

Authors:  Zuo-Long Wu; Ya-Jun Deng; Guang-Zhi Zhang; En-Hui Ren; Wen-Hua Yuan; Qi-Qi Xie
Journal:  Sci Rep       Date:  2020-10-27       Impact factor: 4.379

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.